Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Letting post-marketing bridge the evidence gap: the case of orphan drugs.

× No keyword cloud information.

8 in total

Review 1. [Orphan drugs from the perspective of the Drug Commission of the German Medical Association : Opportunities and challenges].

Authors: Wolf-Dieter Ludwig
Journal: Internist (Berl) Date: 2019-04 Impact factor: 0.743

Review 2. Benefits, benefits, once more benefits... with no risk? Stop overlooking the harms of medicines.

Authors: Silvio Garattini; Vittorio Bertele'
Journal: Eur J Clin Pharmacol Date: 2017-11-27 Impact factor: 2.953

3. Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways.

Authors: Michael Ermisch; Anna Bucsics; Patricia Vella Bonanno; Francis Arickx; Alexander Bybau; Tomasz Bochenek; Marc van de Casteele; Eduardo Diogene; Jurij Fürst; Kristina Garuolienė; Martin van der Graaff; Jolanta Gulbinovič; Alan Haycox; Jan Jones; Roberta Joppi; Ott Laius; Irene Langner; Antony P Martin; Vanda Markovic-Pekovic; Laura McCullagh; Einar Magnusson; Ellen Nilsen; Gisbert Selke; Catherine Sermet; Steven Simoens; Robert Sauermann; Ad Schuurman; Ricardo Ramos; Vera Vlahovic-Palcevski; Corinne Zara; Brian Godman
Journal: Front Pharmacol Date: 2016-09-28 Impact factor: 5.810

Review 4. Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation.

Authors: Patricia Vella Bonanno; Michael Ermisch; Brian Godman; Antony P Martin; Jesper Van Den Bergh; Liudmila Bezmelnitsyna; Anna Bucsics; Francis Arickx; Alexander Bybau; Tomasz Bochenek; Marc van de Casteele; Eduardo Diogene; Irene Eriksson; Jurij Fürst; Mohamed Gad; Ieva Greičiūtė-Kuprijanov; Martin van der Graaff; Jolanta Gulbinovic; Jan Jones; Roberta Joppi; Marija Kalaba; Ott Laius; Irene Langner; Ileana Mardare; Vanda Markovic-Pekovic; Einar Magnusson; Oyvind Melien; Dmitry O Meshkov; Guenka I Petrova; Gisbert Selke; Catherine Sermet; Steven Simoens; Ad Schuurman; Ricardo Ramos; Jorge Rodrigues; Corinne Zara; Eva Zebedin-Brandl; Alan Haycox
Journal: Front Pharmacol Date: 2017-08-23 Impact factor: 5.810

Review 5. A systematic literature review of evidence-based clinical practice for rare diseases: what are the perceived and real barriers for improving the evidence and how can they be overcome?

Authors: Ana Rath; Valérie Salamon; Sandra Peixoto; Virginie Hivert; Martine Laville; Berenice Segrestin; Edmund A M Neugebauer; Michaela Eikermann; Vittorio Bertele; Silvio Garattini; Jørn Wetterslev; Rita Banzi; Janus C Jakobsen; Snezana Djurisic; Christine Kubiak; Jacques Demotes-Mainard; Christian Gluud
Journal: Trials Date: 2017-11-22 Impact factor: 2.279

Review 6. Current landscape of clinical development and approval of advanced therapies.

Authors: Carolina Iglesias-Lopez; Antonia Agustí; Antoni Vallano; Merce Obach
Journal: Mol Ther Methods Clin Dev Date: 2021-11-11 Impact factor: 6.698

Review 7. Methodological Characteristics of Clinical Trials Supporting the Marketing Authorisation of Advanced Therapies in the European Union.

Authors: Carolina Iglesias-Lopez; Antònia Agustí; Antonio Vallano; Merce Obach
Journal: Front Pharmacol Date: 2021-11-29 Impact factor: 5.810

Review 8. How Surrogate and Chemical Genetics in Model Organisms Can Suggest Therapies for Human Genetic Diseases.

Authors: Katherine A Strynatka; Michelle C Gurrola-Gal; Jason N Berman; Christopher R McMaster
Journal: Genetics Date: 2018-03 Impact factor: 4.562

8 in total